Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FE
Fennec Pharmaceuticals Inc. Common Stock
FENC
Mkt Cap
$350.4M
Volume
112.67K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FE
FENC
FE
Fennec Pharmaceuticals Inc. Common Stock
FENC
News
·
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
Mkt Cap
$362.9M
Volume
112.67K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
Southpoint Capital Advisors sold 1 million common shares (2.93%) of Fennec Pharmaceuticals on December 24, 2025, at USD $7.50 per share. The firm retains control of 2.7 million shares (approximately 8% of outstanding shares on a fully diluted basis) and may adjust its position based on market conditions.
GlobeNewswire Inc. · Dec 26, 2025
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
Fennec Pharmaceuticals plans to raise up to $5,025,000 through a non-brokered offering of common shares in Canada at $7.50 per share, with the offering expected to close on November 17, 2025.
GlobeNewswire Inc. · Nov 14, 2025
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
Fennec Pharmaceuticals is conducting a public offering of 4,666,667 common shares at $7.50 per share, expecting to raise approximately $35 million. The proceeds will be used to repurchase debt and for general corporate purposes.
GlobeNewswire Inc. · Nov 14, 2025
Fennec Q2 Sales Jump 33 Percent
Fennec Pharmaceuticals reported strong Q2 2025 earnings with $9.7 million in net product sales, representing 33% year-over-year growth. The company is expanding internationally through partnerships, securing formulary wins, and preparing for potential milestone events in Europe and Japan.
The Motley Fool · Aug 14, 2025
Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.
GlobeNewswire Inc. · Jun 3, 2025
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
Fennec Pharmaceuticals' PEDMARQSI has been approved in the EU and U.K. as the first and only therapy to prevent hearing loss caused by cisplatin chemotherapy in pediatric patients with solid tumors. Norgine Pharmaceuticals has launched PEDMARQSI in Germany, accelerating its global commercialization.
GlobeNewswire Inc. · Feb 7, 2025
Fennec Pharmaceuticals Announces Management Change
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.
GlobeNewswire Inc. · Jul 1, 2024
Fennec Announces Results of Annual Meeting
Annual meeting voting results.
GlobeNewswire Inc. · Jun 25, 2024
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 14, 2024
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~
GlobeNewswire Inc. · May 14, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
FE
FENC
Fennec Pharmaceuticals Inc. Common Stock
Buy
Sell
Market
Limit
Soon
FENC
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any FENC yet.
Related Tickers
Earnings